Our BCR/TCR sequencing, HLA typing sequencing and cancer panel sequencing solutions can assist in the analysis of the tumor microenvironment, providing services for the development of disease mechanisms and therapeutic modalities for immuno-oncology.

CD Genomics offers NGS-based CRISPR/Cas9 screening, validation sequencing and CRISPR off-target discovery solutions. Our gene editing solutions enable the screening and identification of variant genes at any genomic scale, advancing the development of gene editing technology.

Our NGS-based whole exome sequencing, target region sequencing and whole genome sequencing services make up the biomarker discovery solution. The discovery of new biomarkers gives new directions for the prediction and treatment of diseases.

CD Genomics' viral vector development solutions primarily consist of lentiviral/retroviral integration site analysis and AAV sequencing services, which drive the discovery of viral vector development targets and the translational application of recombinant AAV vectors in viral vector development.

In the pharmaceutical area, CD Genomics is able to offer a range of genome sequencing services that can be applied to the development of new drugs and the advancement of precision therapies.

Antibody discovery is important for early research, diagnosis and treatment. Here, CD Genomics offers a high-throughput NGS-based antibody discovery platform that greatly improves the efficiency of antibody discovery.

By combining advanced sequencing technologies and bioinformatic analysis, we provide customized solutions to our clients to help them gain a deeper understanding of eccDNA-driven cancer mechanisms and therapeutic approaches.